This inventor holds 12 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 8 EPO patents. Top assignees: Nof Corporation, Hokkaido University, Chiba University. Active years: 2014-2026.
Location History:
- Hokkaido, JP (2015)
- Sapporo, JP (2014 - 2023)
- Chiba, JP (2024)
Company Filing History:
8 out of 342 
7 out of 442 
4 out of 154 
Years Active: 2014-2026
Title: Hidetaka Akita: Innovator in Cationic Lipids and Recombinant Expression Vectors
Introduction
Hidetaka Akita is a prominent inventor based in Sapporo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of cationic lipids and recombinant expression vectors. With a total of 12 patents to his name, Akita's work has the potential to impact drug delivery systems and mitochondrial disease treatments.
Latest Patents
One of Akita's latest patents is for a cationic lipid exhibiting improved intracellular dynamics. This invention provides a cationic lipid, a lipid membrane structure containing the lipid, and its various uses. The cationic lipid is represented by a specific formula, which is detailed in the patent specification. Another notable patent is for a recombinant expression vector and lipid membrane structure that encapsulates the vector. This invention addresses the need for a novel expression vector capable of effectively expressing a target protein in mitochondria while minimizing undesirable expression in other cell organelles. The recombinant expression vector includes a promoter sequence that exhibits transcription activity in the nuclei of animal cells, allowing for more efficient and selective expression of target proteins in mitochondria.
Career Highlights
Hidetaka Akita has worked with esteemed institutions such as Hokkaido University and Nof Corporation. His research and innovations have garnered attention in the scientific community, particularly for their applications in medicine and biotechnology.
Collaborations
Akita has collaborated with notable colleagues, including Hideyoshi Harashima and Kota Tange. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Hidetaka Akita's innovative work in cationic lipids and recombinant expression vectors showcases his significant contributions to biotechnology. His patents hold promise for improving drug delivery systems and addressing mitochondrial diseases, marking him as a key figure in his field.